|
KR0166088B1
(ko)
|
1990-01-23 |
1999-01-15 |
. |
수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
|
|
US5376645A
(en)
|
1990-01-23 |
1994-12-27 |
University Of Kansas |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
|
US5270163A
(en)
|
1990-06-11 |
1993-12-14 |
University Research Corporation |
Methods for identifying nucleic acid ligands
|
|
US5840867A
(en)
|
1991-02-21 |
1998-11-24 |
Gilead Sciences, Inc. |
Aptamer analogs specific for biomolecules
|
|
GB9126677D0
(en)
|
1991-12-16 |
1992-02-12 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
|
JPH09507211A
(ja)
|
1993-09-14 |
1997-07-22 |
ナショナル ハート アンド ラング インスティチュート |
エオタキシン：好酸球走化性サイトカイン
|
|
JP3367581B2
(ja)
|
1993-10-14 |
2003-01-14 |
小野薬品工業株式会社 |
新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞
|
|
US6806061B1
(en)
|
1995-01-19 |
2004-10-19 |
Children's Medical Center Corporation |
G protein-coupled receptor gene and methods of use therefor
|
|
US6699843B2
(en)
|
1995-06-07 |
2004-03-02 |
Gilead Sciences, Inc. |
Method for treatment of tumors using nucleic acid ligands to PDGF
|
|
AU1208397A
(en)
|
1995-12-28 |
1997-07-28 |
Takeda Chemical Industries Ltd. |
Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
|
|
US6686353B1
(en)
|
1996-05-20 |
2004-02-03 |
Teijin Intellectual Property Center Limited |
Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
|
|
JP2001508798A
(ja)
|
1997-01-21 |
2001-07-03 |
メルク エンド カンパニー インコーポレーテッド |
ケモカインレセプター活性のモジュレーターとしての３，３−二置換ピペリジン類
|
|
CN1248968A
(zh)
|
1997-02-26 |
2000-03-29 |
辉瑞大药厂 |
杂芳基－己酸酰胺衍生物、其制备方法及其作为MIP－1α与其CCRI受体结合的选择性抑制剂的用途
|
|
US6207155B1
(en)
|
1997-05-07 |
2001-03-27 |
Schering Corporation |
Method of eosinophil depletion with antibody to CCR 3 receptor
|
|
GB9711643D0
(en)
|
1997-06-05 |
1997-07-30 |
Janssen Pharmaceutica Nv |
Glass thermoplastic systems
|
|
CA2317895A1
(en)
|
1998-01-15 |
1999-07-22 |
Btg International Limited |
Ribozymal nucleic acids cleaving ccr5 or cxcr4
|
|
EP1056778B1
(en)
|
1998-02-27 |
2007-12-26 |
The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services |
G protein-coupled receptor antagonists
|
|
US6180348B1
(en)
|
1998-04-20 |
2001-01-30 |
Weihua Li |
Method of isolating target specific oligonucleotide ligands
|
|
CA2235420A1
(en)
|
1998-06-17 |
1999-12-17 |
Paolo Renzi |
Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
|
|
AU1408300A
(en)
|
1998-11-24 |
2000-06-13 |
Hisamitsu Pharmaceutical Co. Inc. |
Hiv infection inhibitors
|
|
US6723538B2
(en)
|
1999-03-11 |
2004-04-20 |
Micromet Ag |
Bispecific antibody and chemokine receptor constructs
|
|
AP1654A
(en)
|
1999-03-24 |
2006-09-01 |
Anormed Inc |
Chemokine receptor binding heterocyclic compounds.
|
|
DE60130538T2
(de)
|
2000-02-03 |
2008-06-12 |
Millenium Pharmaceuticals, Inc., Cambridge |
Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
|
|
EP1259615B1
(en)
|
2000-03-03 |
2008-11-12 |
Cambridge Antibody Technology Limited |
Antibodies against eotaxin and their use
|
|
US6946546B2
(en)
|
2000-03-06 |
2005-09-20 |
Cambridge Antibody Technology Limited |
Human antibodies against eotaxin
|
|
GB0016138D0
(en)
|
2000-06-30 |
2000-08-23 |
Novartis Ag |
Organic compounds
|
|
AU2002251913A1
(en)
|
2001-02-02 |
2002-08-19 |
Millennium Pharmaceuticals, Inc. |
Hybrid antibodies and uses thereof
|
|
US20050124569A1
(en)
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
|
|
AU2002357770B2
(en)
|
2001-11-30 |
2008-07-31 |
Biogen Ma Inc. |
Antibodies against monocyte chemotactic proteins
|
|
TW200305395A
(en)
|
2002-03-15 |
2003-11-01 |
Novartis Ag |
Organic compounds
|
|
GB0212357D0
(en)
|
2002-05-29 |
2002-07-10 |
Glaxo Group Ltd |
Novel compounds
|
|
AU2003246587A1
(en)
|
2002-07-02 |
2004-01-23 |
F. Hoffmann-La Roche Ag |
2, 5-substituted pyrimidine derivatives as ccr-3 receptor antagonists ix
|
|
US7964194B2
(en)
|
2002-11-15 |
2011-06-21 |
Morehouse School Of Medicine |
Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation
|
|
CA2516634A1
(en)
|
2003-02-27 |
2004-09-10 |
F. Hoffmann-La Roche Ag |
Ccr-3 receptor antagonists
|
|
US20050069955A1
(en)
|
2003-06-30 |
2005-03-31 |
Daniel Plaksin |
Antibodies and uses thereof
|
|
AR046594A1
(es)
|
2003-10-16 |
2005-12-14 |
Applied Research Systems |
Usos terapeuticos de variantes de quemoquina
|
|
WO2005080410A1
(en)
|
2004-02-20 |
2005-09-01 |
Genesis Research And Development Corporation Limited |
Targeted delivery of rna interference molecules for the treatment of ige-mediated disorders
|
|
AR049386A1
(es)
|
2004-05-26 |
2006-07-26 |
Janssen Pharmaceutica Nv |
Mercaptoimidazoles como antagonistas del receptor ccr2
|
|
EP1802602A1
(en)
|
2004-09-28 |
2007-07-04 |
Janssen Pharmaceutica N.V. |
Substituted dipiperdine ccr2 antagonists
|
|
JP2008535779A
(ja)
|
2005-01-07 |
2008-09-04 |
エモリー・ユニバーシテイ |
Ｈｉｖ感染治療のためのｃｘｃｒ４拮抗薬
|
|
US7622583B2
(en)
|
2005-01-14 |
2009-11-24 |
Chemocentryx, Inc. |
Heteroaryl sulfonamides and CCR2
|
|
PE20061444A1
(es)
|
2005-05-19 |
2007-01-15 |
Centocor Inc |
Anticuerpo anti-mcp-1, composiciones, metodos y usos
|
|
GB0517966D0
(en)
|
2005-09-02 |
2005-10-12 |
Novartis Ag |
Organic compounds
|
|
HUP0500877A2
(en)
|
2005-09-22 |
2007-05-29 |
Sanofi Aventis |
Amide derivatives as ccr3 receptor ligands, process for producing them, pharmaceutical compositions containing them and their use and intermediates
|
|
WO2007147026A2
(en)
|
2006-06-15 |
2007-12-21 |
Centocor, Inc. |
Ccr2 antagonists for chronic organ transplantation rejection
|
|
CA2667547C
(en)
|
2006-10-27 |
2014-07-29 |
Boehringer Ingelheim International Gmbh |
Piperidyl-propane-thiol ccr3 modulators
|
|
US7691813B2
(en)
|
2007-05-30 |
2010-04-06 |
Eli Lilly And Company |
Cyclic peptide CXCR4 antagonists
|
|
CN101820881B
(zh)
|
2007-07-12 |
2013-05-01 |
坎莫森特里克斯公司 |
作为ccr2调节剂用于治疗炎症的稠合杂芳基吡啶基和苯基苯磺酰胺
|
|
WO2009074807A2
(en)
*
|
2007-12-12 |
2009-06-18 |
Imperial Innovations Limited |
Methods
|
|
HUP0800478A2
(en)
|
2008-07-31 |
2010-03-01 |
Sanofi Aventis |
Substituted pyrrolidinyl-[1,3]thiazolo[4,5-b]pyridin derivatives as ccr3 receptor ligands
|
|
WO2010069979A1
(en)
|
2008-12-16 |
2010-06-24 |
Nycomed Gmbh |
Pyran derivatives as ccr3 modulators
|
|
DK2379525T3
(en)
|
2008-12-19 |
2015-10-19 |
Boehringer Ingelheim Int |
Cyclic pyrimidin-4-carboxamides, as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD
|
|
US8278302B2
(en)
|
2009-04-08 |
2012-10-02 |
Boehringer Ingelheim International Gmbh |
Substituted piperidines as CCR3 antagonists
|
|
NZ595432A
(en)
|
2009-04-17 |
2013-12-20 |
Janssen Pharmaceutica Nv |
4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2
|
|
US8471004B2
(en)
|
2009-10-07 |
2013-06-25 |
Hoffman-La Roche Inc. |
Bicyclic compounds
|
|
US8445674B2
(en)
|
2009-10-21 |
2013-05-21 |
Hoffmann-La Roche Inc |
Heterocyclyl compounds
|
|
JP5356323B2
(ja)
*
|
2010-07-01 |
2013-12-04 |
富士化学工業株式会社 |
新規な非晶質ボセンタン及びその製造方法
|
|
US20120088769A1
(en)
*
|
2010-10-11 |
2012-04-12 |
Axikin Pharmaceuticals, Inc. |
Salts of arylsulfonamide ccr3 antagonists
|
|
WO2012075115A1
(en)
|
2010-12-01 |
2012-06-07 |
Janssen Pharmaceutica Nv |
4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of ccr2
|
|
WO2012125662A1
(en)
|
2011-03-17 |
2012-09-20 |
Merck Sharp & Dohme Corp. |
Indole derivatives useful as ccr2 antagonists
|
|
WO2012138880A2
(en)
|
2011-04-07 |
2012-10-11 |
The Brigham And Women's Hospital, Inc. |
Methods of treating inflammatory diseases by targeting the chemoattractant cytokine receptor 2 (ccr2) or chemokine (c-c motif) ligand 2 (ccl2)
|
|
KR20140022048A
(ko)
*
|
2011-05-25 |
2014-02-21 |
인터뮨, 인크. |
선택된 환자에서의 피르페니돈 및 항-섬유성 치료제
|
|
JP6178788B2
(ja)
|
2011-06-27 |
2017-08-09 |
ウニヴェルシテ ピエール エ マリー キュリー（パリ ６） |
Ｃｃｒ２アンタゴニストペプチド
|
|
WO2013052844A1
(en)
*
|
2011-10-07 |
2013-04-11 |
Pulmatrix, Inc. |
Methods for treating and diagnosing respiratory tract infections
|
|
WO2013057545A1
(en)
*
|
2011-10-18 |
2013-04-25 |
Biocon Limited |
Acid addition salts of bosentan
|
|
US8822460B2
(en)
|
2012-04-06 |
2014-09-02 |
Janssen Pharmaceutica Nv |
Fused cyclopentyl antagonists of CCR2
|
|
EP2961398A4
(en)
*
|
2013-03-01 |
2016-09-28 |
Mater Medical Res Inst Ltd |
MOBILIZERS AND USE THEREOF
|
|
WO2014143807A2
(en)
*
|
2013-03-15 |
2014-09-18 |
Stromatt Scott |
Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
|